Inflammation Modulating Activity of the Hydroethanol Stem Bark Extract of *Bombax costatum* in Murine Models

Meshack Antwi-Adjei,¹ Kofi Oduro Yeboah,² James Oppong-Kyekyeku,³ and Newman Osafo²

¹Department of Pharmacology, University of Cape Coast, Cape Coast, Ghana
²Department of Pharmacology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
³Department of Pharmaceutical Chemistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Correspondence should be addressed to Newman Osafo; nosafo.pharm@knust.edu.gh

Received 11 March 2022; Revised 29 June 2022; Accepted 26 July 2022; Published 22 August 2022

Academic Editor: Becky Vonakis

Copyright © 2022 Meshack Antwi-Adjei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Bombax costatum* (Bombacaceae) is traditionally used as a decoction of the leaves, stem, and root to treat headaches, fever, and oedema that may be associated with inflammatory conditions. The aim of this study was to evaluate the effect of 70% v/v ethanolic extract of the stem bark of *Bombax costatum* on acute and chronic inflammation. The effect of *Bombax costatum* extract (10, 50, 100 mg kg⁻¹, p.o) was studied in prostaglandin E₂-induced paw oedema in Sprague–Dawley rats (n = 5). Subsequently, the effect of the extract on clonidine and haloperidol-induced catalepsy was also investigated in ICR mice (n = 5). Finally, the ability of the extract to inhibit chronic inflammation was studied using a rat adjuvant-induced arthritis model. Pre-emptive and therapeutic administration of the extract at all doses significantly suppressed the formation of oedema following prostaglandin E₂ administration. As a measure of indirect antihistaminic effect, treatment with the extract suppressed clonidine-induced catalepsy but not haloperidol-induced catalepsy. Moreover, *Bombax costatum* extract significantly inhibited joint inflammation and damage following injection of complete Freund’s adjuvant. Treatment with the extract also inhibited the onset of polyarthritis; thus, suppressing the systemic spread of joint inflammation from ipsilateral limbs to contralateral limbs. In conclusion, the hydroethanol extract of the stem bark of *Bombax costatum* inhibits both acute and chronic inflammation.

1. Introduction

Inflammation, in its primordial sense, is a beneficial immune response targeted at eliminating offending or phlogistic agents such as bacteria, viruses, and tissue injury [1, 2]. The acute phase of this response is characterized by the rapid influx of granulocytes, immediately followed by the maturation of monocytes into inflammatory macrophages with subsequent functional alteration of resident tissue macrophages [1]. The process is self-limiting and abates once the initiating noxious stimuli are removed via phagocytosis [3]. Nonetheless, the inflammatory response is sometimes dysregulated leading to chronic, persistent inflammation that results in scarring and loss of organ function [4]. The dysregulation and persistence of the inflammatory process play a critical role in the development and progression of many chronic diseases including cancer and autoimmune diseases such as rheumatoid arthritis [1].

Currently, conventional drugs used in the treatment or management of inflammatory disorders include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatoid drugs (DMARDs), and glucocorticoids [5]. Despite the benefit of providing symptomatic relief and slowing the progression of chronic inflammatory disorders (mostly DMARDs), these agents do not ultimately stop the progression of inflammatory diseases, such as arthritis. Moreover, doses associated with maximal efficacies of DMARDs are also associated with significant toxicities; thus, limiting the clinical benefit of these agents [6]. Likewise, NSAIDs and glucocorticoids used in the management of
acute inflammatory disorders and flares in chronic inflammation are associated with significant adverse effects such as gastrointestinal bleeding and immunosuppression, respectively [7]. This highlights the need for newer agents that are more efficacious and less toxic, including those from natural sources.

*Bombax costatum* (Bombacaceae), locally called the red-flowered silk-cotton tree, may be one of such natural sources. The plant is largely distributed in the savanna, dry woodlands from Senegal through West Africa to Southern Chad. This deciduous tree is covered with thick, corky bark and reaches up to about 30 m in height and 100 cm in diameter. The leaves are digitally compound, ovate with 5–7 leaflets and petioles 8–15 cm long. The flowers are solitary, bisexual and 5–7 cm with deep red, orange, or yellow, tulip-shaped, glabrous peduncles. The fruits, contained in ellipsoidal dark-brown capsules, are embedded in white floss called kapok and contain several small seeds [8]. Traditionally, the root decoction is used in the management of epilepsy whereas decoction of the leaves is used in the treatment of fever, headaches, leucorrhoea, diarrhoea, convulsion, and jaundice [9]. Furthermore, stem bark decoction is used in the treatment of skin diseases, trichomoniasis, amoebiasis, and oedema.

As part of our continuous research into medicinal plants, this study aims at establishing the possible anti-inflammatory activity of the hydroethanol extract of the stem bark of *Bombax costatum* in adjuvant-induced arthritis. In addition, the effect of the extract on specific mediators of inflammation is investigated in prostaglandin E2-induced oedema and catalepsy models.

2. Materials and Methods

2.1. Plant Collection and Extraction. The stem bark of *Bombax costatum* was collected from Nkawkaw in the Eastern Region of Ghana between February and April 2019. The bark was subsequently authenticated at the Department of Herbal Medicine, Kwame Nkrumah University of Science and Technology, and a voucher specimen KNUST/HM1/2019/WP006 was deposited in the herbarium of the Department of Herbal Medicine, KNUST. To prepare a hydroethanol extract, the stem bark of the plant was air-dried for 14 days after which it was milled into a coarse powder using a hammer mill (DF-15, DADE, 15 kg/h-110v, HXJQ, China). Afterwards, 600 g of the powder was extracted by cold maceration in 2.0 L of 70% (v/v) ethanol for 72 h following which the supernatant was decanted and filtered. The filtrate was then concentrated at 60°C under low pressure in a rotary evaporator (RE-LA-5, LAB-GENI, China), to obtain a dark-brown liquid which was evaporated to dryness in an oven (MOV-112PE, HXJQ, Panasonic, China) at 60°C over 24 h. The semisoloid concentrate was stored in a desiccator to remove excess moisture. A final percentage yield of 8.76% (\%w) was obtained. Prior to administration throughout the study, the extract was freshly reconstituted in 2% \%x, tragacanth mucilage (dissolved in normal saline), herein referred to as hydroethanol *Bombax costatum* extract (BCE).

\[
\text{\%Yield} = \frac{M_1}{M_0} \times 100\%,
\]

where \(M_0\) was the mass of the stem bark sample and \(M_1\) was the mass of the crude extract.

2.2. Animals. Sprague-Dawley rats (200–250 g) and ICR mice (25–30 g) of both sexes were purchased from Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana. All animals were housed in the Animal facility of the Department of Pharmacology, KNUST. In accordance with Animal Welfare Regulations and the Public Health Service Policy on Humane Care and Use of Laboratory Animals (PHS 2002), all animals used this study were humanely handled throughout the experimental period. Moreover, studies on the rodents were conducted with the approval of the Department of Pharmacology, KNUST Ethics Committee. The animals were randomly grouped (\(n=5\)) and housed in stainless steel cages (34 cm × 47 cm × 18 cm) with softwood shavings as bedding and were fed with a normal commercial pellet diet (GAFCO, Tema, Ghana). All animals were given access to water. The animals were allowed enough time to acclimatize to the new environment and were maintained at a room temperature of 26±2°C in a 12 h light-dark cycle. Each animal was used only once and at the end of each experiment, all animals were euthanized.

2.3. Chemicals and Reagents. Dexamethasone (Pharm-Inter, Brussels, Belgium), metotrexate (Pharm-Inter, Brussels, Belgium), diclofenac (Trogue, Hamburg, Germany), complete Freund’s adjuvant (CFA) (Sigma-Aldrich, St. Louis, MO, USA), clonidine (Teva Ltd, Wakefield, UK); Haloperidol (Alkem, Mumbai, India), chlorpheniramine maleate (Unimark Remedies Ltd, Mumbai, India), and prostaglandin E2 (Boster, CA, USA).

2.4. Microorganism. Heat-killed *Mycobacterium tuberculosis* (strains C, DT, and PN (mixed)) was a kind donation from the Ministry of Agriculture, Fisheries and Food, UK.

2.5. Prostaglandin E2-Induced Paw Oedema in Rats. Paw oedema was induced by subplantar injection of 0.2 ml (1 mM) prostaglandin E2 into the right hind limb of the rats (200–250 g, \(n=5\)) [10]. Rats were treated with either normal saline (1 ml kg\(^{-1}\) p.o.), diclofenac (30 mg kg\(^{-1}\) p.o.), or BCE (10, 50, 100 mg kg\(^{-1}\) p.o.) therapeutically. Using water displacement plethysmography, paw volume was measured before and after PGE\(_2\) induction, at 30 min intervals over 3 h. Oedema was estimated from the percentage change in paw volume over the different time points. The increase in paw volume was expressed using the formula:

\[
\text{%Change in paw volume} = \left[ \frac{(PW_t - PW_0)}{PW_0} \right] \times 100,
\]
where, $P W_0$ and $P W_t$ represent paw volume before and at time, $t$ post PGE$_2$ injection. Total oedema cumulatively induced over 3 h was determined as the area under the time-course curve (AUC), and the percentage inhibition of the total oedema for each treatment was calculated using the formula as follows:

$$\%\text{Inhibition of oedema}=\frac{\text{AUC}_{\text{control}}-\text{AUC}_{\text{treated}}}{\text{AUC}_{\text{control}}}\times 100.$$

(3)

2.6. Clonidine-Induced Catalepsy in Mice. Employing the bar test, the indirect antihistaminic activity of BCE was demonstrated in clonidine-induced catalepsy, defined as maintenance of an imposed posture for a long time before regaining normal posture [11]. Briefly, clonidine (1 mg kg$^{-1}$) was injected subcutaneously into ICR mice (25–30 g, n = 5) and their forepaws were placed on a horizontal bar (1 cm in diameter, 3 cm above a table). The time taken for each animal to remove their paws from the bar, a measure of catalepsy, was recorded and the duration of catalepsy was measured at 30-minute intervals for a total duration of 3 h. Mice received either BCE (10–100 mg kg$^{-1}$, p.o, 1 h), chlorpheniramine maleate (5 mg kg$^{-1}$, ip, 30 min), or 1 ml kg$^{-1}$, p.o of normal saline after catalepsy induction.

2.7. Haloperidol-Induced Catalepsy in Mice. To induce catalepsy, haloperidol (1 mg kg$^{-1}$) was injected subcutaneously into ICR mice (25–30 g, n = 5) and their forepaws were placed on a horizontal bar as described in section 2.6. The time taken for each animal to remove their paws from the bar, a measure of catalepsy, was recorded and the duration of catalepsy was measured at 30-minute intervals for a total duration of 3 h. Mice received either BCE (10–100 mg kg$^{-1}$, p.o, 1 h), normal saline (1 ml kg$^{-1}$, p.o) after catalepsy induction.

2.8. Chronic Inflammation

2.8.1. Induction of Rat Adjuvant-Induced Arthritis. Adjuvant arthritis was induced as previously described by Pearson [12]. Briefly, 100 $\mu$l of complete Freund’s adjuvant (CFA), prepared as a suspension of 5 mg ml$^{-1}$ of heat-killed Mycobacterium tuberculosis (strains C, DT, and PN (mixed)) in paraffin oil, was injected subplantar into the right hind paw of the rats. Nonarthritic control group received only intraplantar injection of 100 $\mu$l of sterile paraffin oil referred to as incomplete Freund’s adjuvant (IFA). Foot volume was measured with a plethysmometer (Ugo Basile S.R.L., Varese, Italy) for both the injected (ipsilateral) and noninjected (contralateral) hind paws prior to intraplantar injection of CFA/IFA (day 0) and daily for 28 days [13]. The oedema component of inflammation was quantified by measuring the difference in foot volume between day 0 and the various time points.

Paw volumes were individually normalized as a percentage of change from their values at day 0 and then averaged for each treatment group. Total oedema induced was measured as the area under the time-course curve (AUC). In a curative study, rats received either vehicle (normal saline), extract (10, 50, and 100 mg kg$^{-1}$, p.o, daily), dexamethasone (3.0 mg kg$^{-1}$, ip every other day), or methotrexate (1.0 mg/kg, ip every 4 days) after induction of oedema on day 14 until the 28th day. All drugs were freshly prepared on each day of drug administration.

2.8.2. Arthritic Indices and Radiological Assessment. A radiological assessment of the severity of cartilage and bone destruction was done on the 29th day. Briefly, rats were anaesthetized with pentobarbitone sodium (20 mg kg$^{-1}$, ip) after which radiographs of the hind paw were taken with an X-ray apparatus [Softex, Tokyo, Japan] and industrial X-ray film (Fuji Photo Film, Tokyo, Japan), at a peak voltage of 30-kV with a 10-s exposure, and a tube-to-film distance of 45 cm for lateral projections. The severity of bone and cartilage damage was blindly scored based on the degree of bone destruction, paw oedema, osteoporosis, and the extent of osteophyte formation [14]. Scoring was done on a scale of 0–3 (0–no degenerative joint changes; 1, slight soft tissue oedema, joint space narrowing, osteolysis, subchondrial erosion, degenerative joint changes; 2, mild to moderate soft tissue oedema, joint space narrowing, osteolysis, subchondrial erosion, degenerative joint changes; 3, severe soft tissue oedema, joint space narrowing, osteolysis, subchondrial erosion, degenerative joint changes).

2.9. Statistical Analysis. All data are presented as Mean±SEM. The time-course curves for changes in paw volume were subjected to a two-way (treatment × time) repeated measures analysis of variance with Tukey’s post hoc test. Differences in AUCs were analysed by one-way ANOVA followed by Tukey’s post hoc test. All graphs were plotted using GraphPad Prism for Windows Version 8.0.1 (GraphPad, San Diego, CA).

3. Results

3.1. Effect of Extract on PGE$_2$-Induced Paw Oedema. Increased release of prostaglandin E$_2$ during acute inflammation contributes to capillary permeability and oedema formation. Doses of the extract were chosen based on the results of an acute toxicity study by Ambi et al. [15]. In this study, the median lethal dose via oral route was greater than 5000 mg/kg in albino rats. The authors then decided to select doses less than one-fourth of the LD$_{50}$ to further reduce any risk of toxicity. From the study, treatment with diclofenac (10, 50, 100 mg kg$^{-1}$), following the PGE$_2$ challenge, significantly ($p < 0.0001$) reduced mean oedema formation over 3 h to $20.43 \pm 6.80\%$ compared to $54.48 \pm 9.98\%$ of the saline-treated control rats (Figures 1(a) and 1(b)). Compared to the saline-control, the extract at doses of 10, 50, and 100 mg kg$^{-1}$ similarly reduced paw swelling significantly ($p < 0.0001$), with mean paw volumes of $39.02 \pm 6.80\%$, $29.37 \pm 5.32\%$, and $22.30 \pm 4.80\%$, respectively (Figure 1(a)). Both the extract and diclofenac significantly suppressed the total oedema induced over 3 h with PGE$_2$ (Figure 1(b)).
3.2. Effect of Extract on Clonidine-Induced Catalepsy.
Catalepsy was observed in all the treatment groups after clonidine (1 mg kg\(^{-1}\)) was administered subcutaneously in the mice. Catalepsy was severest in the saline-control group as shown by displacement of the curve above all other treatment groups (Figure 2(a)). The administration of chlorpheniramine maleate (5 mg kg\(^{-1}\), ip) 30 min after induction of catalepsy significantly \((p < 0.0001)\) reduced the mean duration of catalepsy (5.82 ± 1.12 s) when compared to the saline-control group (19.96 ± 3.95 s). Likewise, treatment with the extract (10, 50, 100 mg kg\(^{-1}\)) significantly \((p < 0.0001)\) suppressed the mean duration of catalepsy to 12.57 ± 2.16 s, 10.11 ± 2.07 s, and 8.14 ± 1.60 s, respectively, compared to 19.96 ± 3.95 s of the saline-treated control (Figure 2(a)). Once again, both chlorpheniramine maleate and the extract significantly \((p < 0.0001)\) reduced the total duration of clonidine-induced catalepsy (Figure 2(b)).

3.3. Effect of the Extract on Haloperidol-Induced Catalepsy.
Haloperidol (1 mg kg\(^{-1}\)) was able to induce catalepsy in all groups, with the highest mean duration occurring in the saline-control group as shown by displacement of the curve above all other treatment groups (Figure 3(a)). Nonetheless, neither treatment produced a statistically significant reduction in catalepsy when compared to the saline-treated control. Treatment with the extract (10, 50, and 100 mg kg\(^{-1}\), p.o.), 1 h after haloperidol administration, exerted no significant \((p > 0.05)\) inhibition on haloperidol-induced catalepsy, with a mean duration of catalepsy of 20.96 ± 4.00 s, 16.89 ± 3 s and 17.54 ± 3.26 s, respectively (Figure 3(a) and 3(b)).

3.3.1. Effect of Extract on Rat Adjuvant-Induced Arthritis.
Complete Freund’s adjuvant inoculation in rats resulted in inflammation of the injected paw (ipsilateral) which spread systemically to the noninjected paw (contralateral) with time. In this study (curative), daily administration of the extract (10, 50, and 100 mg kg\(^{-1}\), p.o.), which commenced on day 14 after injection of CFA significantly suppressed the total oedema induced in rat paws (Figure 4(c)) at the respective doses as compared to the arthritic control group. Similarly, the extract significantly increased total inflammation by 26.14%, 34.07%, and 40.00% in a dose-dependent manner at 10, 50, and 100 mg/kg doses, respectively (Figure 4(d)). There was no significant change in paw volume of the IFA (nonarthritic group) (Figure 4(a)).

3.3.2. Arthritic Indices and Radiological Assessment.
From the study, there were no characteristic signs of joint destruction, cartilage damage, and bone loss of both ipsilateral and contralateral limbs in the IFA (nonarthritic control) group (Figure 5(a)). Arthritic control rats (Figure 5(b)) showed the presence of severe joint destruction, bone loss, and cartilage damage in the ipsilateral limb spreading systemically to the contralateral limb over the 28-day period (Figure 5(b)). The extract at 100 mg kg\(^{-1}\) showed a significant inhibitory effect on bone loss, cartilage damage, and joint destruction in the ipsilateral limb compared to the CFA (Figure 5(b)). However, there was no significant inhibition observed in the contralateral limb as compared to the CFA (arthritic control group) (Figures 5(e)–5(g)). The respectively scored arthritic indices of the rats reflected the observations made from the radiographs as enshrined in the table (Table 1).
4. Discussion

Inflammatory response against invading pathogens or noxious stimuli is primarily aimed at eliminating tissue insults, resolving internal perturbations, and returning the body to homeostasis [16]. Despite this protective intent, the inflammatory process, either acute or chronic, often goes awry and contributes to the pathogenesis of many diseases including rheumatoid arthritis, cancer, and cardiovascular diseases [17, 18]. The effect of the hydroethanol extract of the stem bark of Bombax costatum was therefore investigated in acute and chronic inflammatory models.

In this study, Bombax costatum extract inhibited prostaglandin E\textsubscript{2} (PGE\textsubscript{2})-induced paw oedema. The biosynthesis of
prostaglandins is dysregulated and significantly increased in inflamed tissues and has been associated with the progression of the inflammatory response [1]. Specifically, dysregulated synthesis and degradation of PGE2, one of the most abundant prostaglandins, contributes to the development of processes that result in the development of all the cardinal signs of inflammation [18]. Interestingly, PGE2 has been shown to mediate the development of paw oedema following subplantar injection of collagen. This superfluous oedema occurs as a result of PGE2’s activity on the cognate EP2 and EP4 receptors [19, 20]. Similarly, EP2 and EP3 receptor stimulation by PGE2 produced during carrageenan-induced paw oedema and carrageenan-induced pleurisy, have been shown to cause inflammatory exudation [21]. From this study, it can be posited

Figure 4: Bombax costatum extract inhibits adjuvant-induced arthritis. Values are mean ± SEM (n = 5). ### $p < 0.001$; #### $p < 0.0001$ compared to contralateral paw (two-way ANOVA followed by Tukey’s post hoc test). *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$, and **** $p < 0.0001$, respectively, compared to the control-treated group (one-way ANOVA followed by Turkey’s post hoc test). Arrow indicates the day of drug commencement.
that *Bombax costatum* extract inhibits late-phase acute inflammatory response, through inhibition of PGE₂ activity.

Additionally, the extract was also found to inhibit clonidine-induced catalepsy, a measure of the extrapyramidal effect of a drug. As such, the antioedematogenic effect of *Bombax costatum* extract may not only be mediated via inhibition of PGE₂ activity, but the activity of histamine as well. To clarify, drugs that induce catalepsy achieve this effect through inhibition of dopaminergic transmission or the enhancement of histamine release in the brain [22]. One of such drugs is clonidine, a presynaptic α₂-adrenoceptor agonist, that dose-dependently induces catalepsy via the enhancement of histamine release from mast cells in the brain [23]. This effect can be blocked by histamine H₁ receptor antagonists but not H₂ receptor antagonists [24]. Haloperidol, on the other hand, induces catalepsy through dopamine D₂ receptor antagonism [25]. Thus, the lack of inhibition against haloperidol-induced catalepsy implies the

---

**Figure 5:** Effect of *Bombax costatum* extract on adjuvant-induced arthritis in rats. (a) Incomplete Freund’s adjuvant (nonarthritic) group, (b) complete Freund’s adjuvant (arthritic control) group, (c) methotrexate (1.0 mg/kg, ip), (d) dexamethasone (3.0 mg/kg, ip), and (e)–(g) extract (10–100 mg/kg, p.o.), respectively.
absence of dopamine D2 activity by the extract. Thus, inhibition of catepsay following clonidine administration suggests that Bombax costatum extract possesses histamine H1 antagonistic properties.

Moreover, mast cells are the major source of histamine in body tissues and are known to highly express histamine H4 receptors on their surfaces [26]. Stimulation of the H4 receptor on mast cells causes degranulation and mediates the proinflammatory response of histamine, through the activation of mitogen-activated protein kinases [27]. Additionally, activation of the receptor increases the expression of adhesion molecules, rearrangement of cytoskeleton, and changes in cell shape. Subsequently, these histamine-mediated responses increase immune cell migration to the site of inflammation leading to the development of the classic signs of inflammation such as oedema [28]. Furthermore, the H4 receptor-mediated activation of mast cells increases the stimulation of proinflammatory cytokine release, including the release of interleukin-6 and tumour necrosis factor-α [29, 30]. For this reason, the antihistaminic effect of Bombax costatum extract may possibly indicate the ability to inhibit mast cell degradation. However, further investigation is needed to confirm this proposed mast cell stabilizing property of the extract during acute inflammation.

Likewise, Bombax costatum extract was identified to suppress chronic inflammation associated with adjuvant-induced arthritis. This model is a chronic inflammatory model widely utilized in the preclinical screening of anti-inflammatory agents used in the management of rheumatoid arthritis [31, 32]. Injection of heat-killed Mycobacterium tuberculosis induces autoimmune inflammation that is characterized like an immunological response in human rheumatoid arthritis. In the same way, adjuvant-induced arthritis is characterized by cellular infiltration of the synovial membrane and joint destruction which resembles the human disease [33].

In this study, treatment with Bombax costatum extract reduced the synovitis, swelling, and joint inflammation associated with adjuvant-induced arthritis. Furthermore, the extract reduced joint inflammation with minimal joint deformation and narrowing. This antiarthritic effect of the extract can be attributed in part to the inhibition of PGE2 synthesis and activity, as previously shown. This is because, PGE2 produced in rheumatoid synovium, via activation of EP4 receptors, contributes to IL-6 production and joint destruction [34, 35]. This is supported by findings that mice that have EP1, EP2, or EP3 receptors but are deficient in EP4 show an attenuated response to joint inflammation, with significantly lower levels of IL-6 and IL-1 and a dramatic reduction in the disease severity [36]. Thus, through the inhibition of PGE2-EP4 activity, the extract inhibited the development and progression of arthritic features following injection of complete Freund’s adjuvant (CFA).

Like human rheumatoid arthritis, rat adjuvant-induced arthritis is generally a systemic illness, with inflammation that spreads and affects tarsal and phalangeal joints, even of the uninjected paw, after 11–16 days [37]. This is known as polyarthritis. Interestingly, treatment with Bombax costatum extract was able to inhibit the development of polyarthritis on day 13 post-CFA injection. This implies that the extract can suppress and limit the spread of joint inflammation to unaffected joints. This anti-inflammatory activity of Bombax costatum extract may be associated with the presence of catechin-7-O-glucoside [38]. The pharmacological properties of catechins have been extensively studied to reveal their anti-inflammatory effects. For instance, catechins have been shown to inhibit TNF-α and NF-κB pathways and the release of nitric oxide in acute and chronic inflammation [39, 40]. Thus, in human rheumatoid arthritis, Bombax costatum extract may serve as a source of drug leads that can inhibit or delay the onset of polyarthritis and other associated systemic manifestations, such as ocular, nasal, dermal, and metabolic manifestations [37].

| Groups       | Radiological index | Ipsilateral | Contralateral |
|--------------|--------------------|-------------|---------------|
|              |                    |             |               |
| IFA          | 0                  | 0           | 0             |
| CFA          | 2.60 ± 0.25        | 2.40 ± 0.25 |               |
| Methotrexate | 1.0 mg/kg          | 2.40 ± 0.24 | 2.20 ± 0.20   |
| Dexamethasone| 3.0 mg/kg          | 1.80 ± 0.20 | 2.00 ± 0.31   |
| Extract      | 10 mg/kg           | 1.40 ± 0.24 | 1.80 ± 0.20   |
|              | 50 mg/kg           | 1.80 ± 0.20 | 2.00 ± 0.31   |
|              | 100 mg/kg          | 1.40 ± 0.24 | 1.80 ± 0.20   |

One-way ANOVA followed by Turkey’s post hoc test. All data are presented as mean ± SEM (n = 5). *P < 0.05, ** p < 0.01, and *** p < 0.001 compared to the complete Freund’s adjuvant control group. CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s adjuvant.

5. Conclusion
Given the above, the hydroethanolic extract of Bombax costatum is effective against acute and chronic inflammation. This study has shown for the first time that, Bombax costatum extract suppresses oedema associated with acute inflammation through the inhibition of the action of prostaglandin E2 and histamine. Moreover, our findings also suggest that Bombax costatum extract may be a potential source of lead compounds, for use in the management of rheumatoid arthritis.

Data Availability
All data are available on request.

Ethical Approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Department of Pharmacology Ethical Committee (Approval date: 4th January 2019; Approval Number: EC-COL/2019/010).
Conflicts of Interest

The authors have no conflicts of interest to disclose.

Authors’ Contributions

MA-A designed the study, collected data, and drafted the manuscript. KOY analysed and interpreted data, and drafted the manuscript. JO-K reviewed, edited and critically revised the manuscript. MA-A designed the study, interpreted and critically revised the manuscript. All authors read and approved the final version to be published. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Mr. Thomas Anshah, formerly of the Department of Pharmacology, KNUST, for offering them technical support in carrying out this project.

References

[1] E. Ricciotti and G. A. FitzGerald, "Prostaglandins and inflammation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 986–1000, 2011.
[2] D. E. B. Baldo and J. E. Serrano, "Screening for intestinal anti-inflammatory activity Alpinia galanga against acetic acid-induced colitis in mice," Journal Medicinal Plants, vol. 4, no. 1, pp. 72–77, 2017.
[3] L. B. Correa, T. A. Padua, L. N. Seito et al., "Anti-inflammatory in vitro and in vivo effect of methyl gallate on experimental arthritis: inhibition of neutrophil recruitment, production of inflammatory mediators, and activation of macrophages," Journal of Natural Products, vol. 79, no. 6, pp. 1554–1566, 2016.
[4] Z. H. Nemeth, D. A. Bogdanovski, P. Barratt-Stopper, S. R. Paglinco, L. Antonioli, and R. H. Rolandelli, "Crohn’s disease and ulcerative colitis show unique cytokine profiles," Cereus, vol. 9, no. 4, p. e1177, 2017.
[5] B. Ungar and U. Kopylov, "Advances in the development of new biologics in inflammatory bowel disease," Annals of Gastroenterology, vol. 29, no. 3, pp. 243–248, 2016.
[6] A. Amoroso, A. Gigante, C. Gianni et al., "Safety of conventional drugs and biologic agents for Rheumatoid Arthritis," European Review for Medical and Pharmacological Sciences, vol. 7, no. 5, pp. 139–145, 2003.
[7] D. D. Obiri, N. Osapo, P. G. Ayande, and A. O. Antwi, "Xylopia aethiopica (Annonaceae) fruit extract suppresses Freund’s adjuvant-induced arthritis in Sprague-Dawley rats," Journal of Ethnopharmacology, vol. 152, no. 3, pp. 522–531, 2014.
[8] L. P. A. Oyen, "Bombax costatum pellegr.and vuillet prota," 2011, https://www.prota4u.org/database/protar8.asp?g=pe&f=Bombax+costatum+pellegr.&v=Vuillet.
[9] C. Orwa, A. Mutua, R. Kindt, R. Jamnadass, and S. Anthony, "Agroforestry database: a tree reference and selection guide version 4.0," 2009, https://www.worldagroforestry.org/sites/treebbs/treedatabases.asp.
[10] U. K. Mazumder, M. Gupta, L. Manikandan, S. Bhattacharya, P. K. Haldar, and S. Roy, "Evaluation of anti-inflammatory activity of Vernonina cinerea Less. Extract in rats," Phytomedicine, vol. 10, no. 2-3, pp. 185–188, 2003.
[11] S. Ferré, T. Guix, G. Prat, F. Jane, and M. Casas, "Is experimental catalepsy properly measured?" Pharmacology Biochemistry and Behavior, vol. 35, no. 4, pp. 753–757, 1990.
[12] C. M. Pearson, "Development of arthritis, periarteritis and periostitis in rats given adjuvants," Experimental Biology and Medicine, vol. 91, no. 1, pp. 95–101, 1956.
[13] M. Fereidoni, A. Ahmadiani, S. Semmanian, and M. Javan, "An accurate and simple method for measurement of paw edema," Journal of Pharmacological and Toxicological Methods, vol. 43, no. 1, pp. 11–14, 2000.
[14] X. Cai, H. Zhou, Y. F. Wong et al., "Suppression of the onset and progression of collagen-induced arthritis in rats by QFGJS, a preparation from an anti-arthritis Chinese herbal formula," Journal of Ethnopharmacology, vol. 110, no. 1, pp. 39–48, 2007.
[15] A. A. Ambi, A. Abubakar, and M. Z. Hassan, "Acute toxicity studies and antibacterial evaluation of Bombax costatum stem bark extracts," Journal of Pharmacy and Bioresources, vol. 15, no. 2, p. 139, 2018.
[16] M. E. Kotas and R. Medzhitov, "Homeostasis, inflammation, and disease susceptibility," Cell, vol. 160, no. 5, pp. 816–827, 2015.
[17] C. Caruso, D. Lio, L. Cavallone, and C. Franceschi, "Aging, longevity, inflammation, and cancer," Annals of the New York Academy of Sciences, vol. 1028, pp. 1–13, 2004.
[18] C. E. Finch, "Developmental origins of aging in brain and blood vessels: an overview," Neurobiology of Aging, vol. 26, no. 3, pp. 281–291, 2005.
[19] C. D. Funk, "Prostaglandins and leukotrienes: advances in eicosanoid biology," Science, vol. 294, no. 5548, pp. 1871–1875, 2001.
[20] K. Kabashima, T. Saji, T. Murata et al., "The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut," Journal of Clinical Investigation, vol. 109, no. 7, pp. 883–893, 2002.
[21] K. i Yuhki, A. Ueno, H. Naraba et al., "Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy," Journal of Pharmacology and Experimental Therapeutics, vol. 311, no. 3, pp. 1218–1224, 2004.
[22] S. Nirmal, R. Rathi, R. Laware, V. Dhasade, and B. Kuchekar, "Antihistaminic effect of Bauhinia racemosa leaves," Journal of Young Pharmacists, vol. 3, no. 2, pp. 129–131, 2011.
[23] M. S. Rakh, D. N. Raut, M. J. Chavan, and S. R. Chaudhari, "Effect of various extracts of Momordica dioica Pulp on clonidine and haloperidol-induced catalepsy in mice," Pharmacologyonline, vol. 1, pp. 1–11, 2010.
[24] J. H. Jadhav, J. J. Balsara, and A. G. Chandorkar, "Involvement of histaminergic mechanisms in the catecholpigenetic effect of clonidine in mice," Journal of Pharmacy and Pharmacology, vol. 35, no. 10, pp. 671–673, 2011.
[25] A. C. Colombo, A. R. de Oliveira, A. E. Reimer, and M. L. Brandão, "Dopaminergic mechanisms underlying catalepsy, fear and anxiety: do they interact?" Behavioural Brain Research, vol. 257, pp. 201–207, 2013.
[26] E. B. Thangam, A. E. Jemima, H. Singh et al., "The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets," Frontiers in Immunology, vol. 9, p. 1873, 2018.
[27] C. L. Hofstra, P. J. Desai, R. L. Thurmond, and W. P. Fung-Leung, "Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells," Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 1212–1221, 2003.

Leung, "Histamine H4 receptor mediates chemotaxis and Experimental catalepsy properly measured?" Behavioral Brain Research, vol. 257, pp. 201–207, 2013.
[28] K. F. Buckland, T. J. Williams, and D. M. Conroy, “Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor,” *British Journal of Pharmacology*, vol. 140, no. 6, pp. 1117–1127, 2003.

[29] E. A. Jemima, A. Prema, and E. B. Thangam, “Functional characterization of histamine H4 receptor on human mast cells,” *Molecular Immunology*, vol. 62, no. 1, pp. 19–28, 2014.

[30] S. N. Abraham and A. L. St John, “Mast cell orchestrated immunity to pathogens,” *Nature Reviews Immunology*, vol. 10, no. 6, pp. 440–452, 2010.

[31] T. Fumoto, S. Takeshita, M. Ito, and K. Ikeda, “Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis,” *Journal of Bone and Mineral Research*, vol. 29, no. 4, pp. 830–842, 2014.

[32] A. J. Giles, M. K. N. D. Hutchinson, H. M. Sonnemann et al., “Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy,” *Journal for ImmunoTherapy of Cancer*, vol. 6, no. 1, 2018.

[33] J. A. Singh, K. G. Saag, S. L. Bridges et al., “American college of rheumatology guideline for the treatment of rheumatoid arthritis,” *Arthritis and Rheumatology*, vol. 68, no. 1, pp. 1–26, 2016.

[34] J. P. Portanova, Y. Zhang, G. D. Anderson et al., “Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo,” *Journal of Experimental Medicine*, vol. 184, no. 3, pp. 883–891, 1996.

[35] X. Zhang, Y. Dong, H. Dong, W. Zhang, and F. Li, “Investigation of the effect of Phlomisoid F on complete Freund’s adjuvant-induced arthritis,” *Experimental and Therapeutic Medicine*, vol. 13, no. 2, pp. 710–716, 2017.

[36] J. M. McCoy, J. R. Wicks, and L. P. Audoly, “The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis,” *Journal of Clinical Investigation*, vol. 110, no. 5, pp. 651–658, 2002.

[37] C. M. Pearson and F. D. Wood, “Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant. I. General clinical and pathologic characteristics and some modifying factors,” *Arthritis and Rheumatism*, vol. 2, no. 5, pp. 440–459, 1959.

[38] H. A. Bila, M. Ilyas, A. M. Musa et al., “Isolation of catechin glucoside from the root bark of bombax costatum (Bombacaceae),” *Nigerian Research Journal of Chemical Sciences*, vol. 9, no. 1, pp. 207–214, 2021.

[39] X. Zeng, Q. Qiu, C. Jiang, Y. Jing, G. Qiu, and X. He, “Antioxidant flavanes from Livistona chinensis,” *Fitoterapia*, vol. 82, no. 4, pp. 609–614, 2011.

[40] Y. Luo, Y. Jian, Y. Liu, S. Jiang, D. Muhammad, and W. Wang, “Flavanols from nature: a phytochemistry and biological activity review,” *Molecules*, vol. 27, no. 3, p. 719, 2022.